Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB3 | P13945 | 1/20 | 0.40 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.40 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.40 |
| ▸ | CTSB | P07858 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.32 |
| ▸ | ABCG2 | Q9UNQ0 | 2/20 | 0.31 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.31 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14438722 | 1.00 | ADRB3 (0.40) | ADRB3ADRA2BADRA2CCTSBPDE4B | |
| SCHEMBL14438723 | 0.85 | ADRB3 (0.36) | ADRB3ADRA2BADRA2CCTSBCYP3A4 | |
| SCHEMBL14031130 | 0.85 | ADRB3 (0.36) | ADRB3ADRA2BADRA2CCTSBCYP3A4 | |
| SCHEMBL13915585 | 0.85 | ADRB3 (0.52) | ADRB3ADRA2BADRA2CCTSBPDE4B | |
| SCHEMBL14031195 | 0.85 | ADRB3 (0.52) | ADRB3ADRA2BADRA2CCTSBPDE4B | |
| SCHEMBL14049098 | 0.83 | ADRB3 (0.39) | ADRB3ADRA2BADRA2CCTSBPDE4B | |
| SCHEMBL13915582 | 0.79 | ADRB3 (0.58) | ADRB3ADRA2BADRA2CCTSBCYP3A4 | |
| SCHEMBL14031132 | 0.78 | GAA (0.35) | PDE4B | |
| SCHEMBL14049427 | 0.76 | ADRB3 (0.51) | ADRB3ADRA2BADRA2CCTSBPDE4B | |
| SCHEMBL5155411 | 0.76 | ADRB3 (0.58) | ADRB3ADRA2BADRA2CCTSBABCG2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442695-B2 | Depeptidized inhibitors of hepatitis C virus NS3 protease | SCHERING CORPORATION (US) | 2008-10-28 | — | — | US | disclosed |
| US-20070258947-A1 | Depeptidized Inhibitors of Hepatitis C Virus NS3 Protease | SCHERING CORPORATION | 2007-11-08 | — | — | US | disclosed |
| US-7253160-B2 | Depeptidized inhibitors of hepatitis C virus NS3 protease | SCHERING CORPORATION (US) | 2007-08-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070258947-A1 | Depeptidized Inhibitors of Hepatitis C Virus NS3 Protease | DPP3, DPP7, DPP4 | ADRB3 3738/4885ADRA2B 4407/4885ADRA2C 4161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.